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CC BY-NC-ND license (http://creativeAbstract Objective: To assess the effectiveness and safety of acupoint injection for the
treatment of asthma.
Methods: Six electronic databases were searched for randomized controlled trials (RCTs) of
acupoint injection for asthma. Two authors extracted data and assessed methodological qual-
ity independently using the Cochrane Collaboration Risk of Bias tool. Data were evaluated us-
ing RevMan v5.2.
Results: Eighteen RCTs involving 1913 participants with asthma were identified. Overall meth-
odological quality of the RCTs was classified as unclear risk of bias. Western medicine (12 RCTs)
was injected most frequently into acupoints, followed by Chinese herbal medicine (four RCTs),
vitamins (one RCT), and Chinese herbal medicine combined with Western medicine (one RCT).
Four RCTs used only one acupoint [ST36 (two RCTs), BL13, CV22], whereas the other RCTs
selected multiple acupoints (among which BL13 was used most frequently). One RCT reported
mortality, no RCT reported quality of life, 15 RCTs reported the symptom improvement rate,
one RCT reported asthma control test (ACT) data, one RCT reported the duration of asthma,
three RCTs reported the mean time that asthma was controlled (MTAC), and 13 RCTs reported
lung-function tests (LFTs). Some RCTs showed acupoint injection may improve the attack time
of asthma, MTAC, and LFTs. Five RCTs reported the outcome of adverse events and showed no
significant differences between the acupoint injection group and control group.
Conclusions: The findings suggest that acupoint injection may be effective for improving ACT
data, duration of asthma, MTAC and LFTs. However, the evidence is insufficient owing to the
poor methodological quality of the RCTs.0 6428 7002; fax: þ86 10 6428 6871.
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Asthma is a chronic inflammatory airway disorder charac-
terized by hypersensitivity to various stimuli as well as
widespread, episodic, airway obstruction. Worldwide, it
affects 300 million people of all ages.1,2 Typical symptoms
are wheezing, coughing, chest tightness, and dyspnea.3
Left uncontrolled, asthma can limit daily activities of life
and even lead to death.4
Inhaled corticosteroids are the drugs of choice for
relieving asthma symptoms, but are not effective in some
patients.5 Moreover, no treatment for asthma has long-term
efficacy for inflammation or remodeling of the airways.
Hence, no treatment can modify or cure asthma.6
In traditional Chinese medicine (TCM), asthma falls
under the category of xiao (wheezing) syndrome and chuan
(panting) syndrome. One of the earliest records of the
condition is found in the Han dynasty (circa 200 CE) text,
The Yellow Emperor’s Inner Classic (Huang Di Nei Jing). It
was not until the Yuan dynasty (1300s CE) that the
renowned physician Zhu Danxi introduced the concept of
xiaochuan (asthma) as an independent disease.7 The
earliest description of infantile asthma is found in the Ming
dynasty (1549) text Elaboration of Pediatrics: Asthma (You
Ke Fa Hui: Xiao Chuan).
To treat an asthma attack, when symptoms are present,
the principle is to dispel pathogens. This is known as
“treating the branch” (symptoms). During asymptomatic
periods, the principle of treatment is to reinforce the
body’s energy (qi). This is known as “treating the root.”
Acupoint injection therapy involves injecting medicine
(Chinese herbal extractions, Western medications, vita-
mins, normal saline etc.) into certain acupoints or specific
sites based on TCM theories of symptom differentiation and
treatment. The advantage of the therapy is that both
needling stimulation and administration of medicines are
accomplished simultaneously.8 Nowadays, some systematic
reviews have demonstrated that acupoint injection therapy
could prevent postoperative ileus and manage burning
mouth syndrome.9,10 Meanwhile, certain randomized
controlled trials (RCTs) indicate that acupoint injection
with either Western medicine or Chinese herbal medicine
can improve symptom of patients with asthma.
We studied all RCTs on acupoint injection for asthma
treatment and evaluated their methodological quality to
ascertain the therapeutic effectiveness and safety of acu-
point injection for asthma.
Materials and methods
Search strategy
We searched four Chinese (China National Knowledge
Infrastructure, Chinese Science and Technology Periodical,
Wanfang, SinoMed) and two English databases (PubMed,Cochrane Library). English search terms were “acupoint
injection”, “acupuncture point injection”, and “asthma”.
Chinese search terms used alone or in combination were
“xuewei zhushe (acupoint injection)”, “shuizhen (fluid
needle injection)”, “xiaochuan (asthma)”, “xiaozheng
(asthma syndrome)”, “qichuan (layterm for asthma)”. The
retrieval mode was adjusted to different databases so that
it could be based on MeSH terms or keywords/abstracts to
ensure comprehensiveness. These electronic databases
were searched from their inception until December 15,
2013. No language restriction was applied.Inclusion criteria
We included RCTs on acupoint injection for treatment of
participants diagnosed with asthma. We did not limit the
type of medications injected: they could be Western drugs
or Chinese herbal medicines, or a combination of Western
drugs and Chinese herbal medicines. Control interventions
could be no treatment, placebo or Western therapy. Co-
intervention(s) was allowed as long as they were applied in
both groups. Primary outcomes were mortality, quality of
life (QoL), symptom improvement rate, asthma control test
(ACT), duration of asthma mean time that asthma was
controlled (MTAC). Secondary outcomes were lung-function
tests [LFTs, peak expiratory flow (PEF), forced expiratory
volume in one second (FEV1), forced vital capacity (FVC),
vital capacity (VC)], cost-effectiveness, and adverse
events.Study selection
Study selection involved seven steps: (1) importing studies
obtained from different databases into reference-
management software (NoteExpress v2.8.1); (2) using
NoteExpress to remove duplications; (3) excluding obvi-
ously unrelated articles by reading titles and summaries; (4)
retrieving full texts of research reports that may be rele-
vant to our systematic review; (5) deleting studies that did
not meet the inclusion criteria; (6) combining articles that
reported the same study and removing duplicate articles;
(7) making the final decision of study selection.
Two authors (P Xue and LQ Wang) identified studies that
met the inclusion criteria independently. Discrepancies
were identified and resolved by discussion through a third
author (JP Liu).Data extraction
Data were extracted by one author (WY Li) using a self-
designed data-extraction table, and verified by another
author (LQ Wang). Uncertainties were discussed by the two
authors. Extracted information was study methodology,
sample size of each group, demographic characteristics of
24 P. Xue et al.participants, details of intervention and control conditions,
and outcomes.
Assessment of methodological quality
Two authors (LQ Wang and WY Li) assessed the methodo-
logical quality of RCTs using the Cochrane Collaboration
Risk of Bias tool.11 As recommended by the Cochrane
Collaboration, we assessed seven domains: sequence gen-
eration, allocation concealment, blinding of participants
and personnel to the study protocol, blinding of outcome
assessors to the study protocol, incomplete outcome data,
selective reporting of outcomes, and other biases (baseline
comparability between groups). The risk of bias of included
RCTs was categorized as “low”, “unclear”, or “high” risk of
bias in accordance with Cochrane guidelines.
Data analyses
We undertook meta-analysis of the RCTs among which
intervention and control conditions were identical or
similar using RevMan v5.2 provided by the Cochrane
Collaboration. Continuous data were summarized using
weighted mean difference (MD) with 95% confidence in-
tervals (CIs) and dichotomous outcomes using relative risk
(RR) with 95% CIs. If significant heterogeneity among RCTs
was noted, a random-effects model was applied. If signifi-
cant heterogeneity among RCTs was not observed, a fixed-
effects model was used. For data that could not be evalu-
ated, we provided qualitative descriptions. Acupoint in-
jection alone in the intervention group and acupoint
injection in combination with other interventions in the
intervention group were analyzed separately.
Results
Description of studies
The initial search on December 15, 2013 yielded 310 arti-
cles related to acupoint injection for asthma treatment
from six databases. After reading titles and abstracts, 251
of these articles were excluded because they were dupli-
cates, nonclinical studies, or had study objectives different
from those of our systematic review. By reading full texts,
articles that did not meet the inclusion criteria were
excluded (Fig. 1). In the end, 18 RCTs (19 articles) met the
eligibility criteria for this review.
Participants
Eighteen RCTs (19 articles)12e29 involving 1913 participants
with asthma were included in our systematic review. Mean
size of RCTs was 106 (56e208) patients per RCT. Two
RCTs19,28 recruited inpatients, two RCTS12,24 outpatients,
five RCTs16,18,23,25,29 outpatients and inpatients, one RCT26
outpatients, in-patients and emergency patients, and one
RCT27 outpatients and nursing-home patients. The remain-
ing seven RCTs13e15,17,20e22 did not specify patient settings.
Subjects were children in three RCTs,14,15,28 and geriatric
subjects in one RCT,27 whereas the other RCTs did not
report the age group of patients. Ninestudies13,16,19e21,25e27,29 reported asthma types, among
which one RCT29 was in clinical remission and the others in
the acute-attack stage (Table 1).
Diagnosis
Fifteen RCTs12e19,22e28 reported diagnostic standards,
including the: Bronchial Asthma Prevention Guide (1997,
2008) by the Chinese Medical Association Respiratory Dis-
eases Branch Asthma Study Group (CMARDBASG) in six
RCTs12,16,18,19,24,27; Definition, Diagnosis, Severity Grade
and Therapeutic Effect Standard (Revised version) (1993)
by the CMARDBASG in three RCTs22,23,26; Children Bronchial
Asthma Prevention Practices (Trial) (2004) by the Chinese
Medical Association Pediatrics Branch Respiratory Study
Group in two RCTs15,28; other standards in four
RCTs13,14,17,25 (Table 1).
Interventions
All included RCTs had a two-arm design, except for three
RCTs that were three-armed.17,18,23 No RCTs compared
acupoint injection with no treatment or placebo. Seven
RCTs13,17,22e24,26,29 compared acupoint injection with
Western medicine, eight RCTs14e16,18e21,28 compared acu-
point injection plus basic treatment with basic treatment,
and three RCTs12,25,27 compared acupoint injection plus
basic treatment with Western medicine plus basic treat-
ment. Basic treatment in included RCTs was symptomatic
treatment (e.g., diminishing inflammation, resolving
phlegm, relieving spasm and panting). Various medicines
were used in the 18 RCTs: Western medicine in 12
RCTs,12e14,19e24,26e28 Chinese herbal medicine in four
RCTs,15,16,18,25 vitamins in one RCT,17 and Western medicine
combined with Chinese herbal medicine in one RCT.29 Ba-
cillus CalmetteeGuerin polysaccharide nucleic acid (BCG-
PSN) was the most used Western medicine in four
RCTs,12,14,22,23 and Chuankezhi injection was the most used
Chinese herbal medicine in three RCTs.15,16,18 Four
RCTs13,14,17,21 used only one acupoint [ST-36 (two RCTs),
BL13, CV22], whereas the others used multiple acupoints,
among which BL13 was used most frequently, followed by
EX-B1, ST-36, and CV22. Mean duration of treatment was 32
days (range, 6 h to 3 months) (Table 2).
Outcomes
In terms of primary outcomes, one RCT20 reported mortal-
ity, and none of the other 18 RCTs reported QoL. Fifteen
RCTs12,15,17e29 reported the symptom improvement rate
(including relief/amelioration of symptoms), among which
nine12,15,17,18,21e23,27,28 described the pre-defined criteria
for effectiveness. One RCT12 reported ACT results, one
RCT14 reported the duration of asthma, and three
RCTs13,21,28 reported the MTAC.
For secondary outcomes, 13 RCTs12,13,15e21,24e26,29 re-
ported the outcomes of LFTs (FEV1, PEF, FVC). Five
RCTs12,14,24,27,29 reported the outcome of adverse events
(including local skin redness, swelling, pain). No RCT re-
ported cost-effectiveness. Six RCTs12,14,16,19,27,29 reported
follow-up duration after completion of treatment ranging
from 1 month to 1 year (median duration, 6 months).
However, the follow-up information of included RCTs was
not available (Table 2).
Fig. 1 Flowchart of study selection.
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Fourteen of the RCTs did not report the methods of
randomization, except for four RCTs in which SPSS statis-
tical software12 and random number tables15,18,25 were
applied. Only one RCT12 provided information about allo-
cation concealment using sealed envelopes. With regard to
performance bias, all RCTs were perceived to be high risk
because no study used a placebo or other methods to blind
participants and personnel to the study protocol. With
respect to detection bias, only one RCT12 which blinded the
outcome assessors and statistician was considered to be low
risk, and two RCTs which reported that they used binding
but did not specify who was blinded had an unclear risk of
bias. In terms of attrition bias, three RCTs12,14,26 were
considered to be of high risk. Of these, one RCT reported
the prevalence of dropouts before the end of treatment12
but failed to provide reasons and did not use intention-to-
treat analyses to handle missing data, and the other two
RCTs14,26 had missing data but did not mention why.
Accessible protocols of any included RCTs were not avail-
able, so we had to compare the Methods sections with
Results sections for assessment of reporting bias. ThreeRCTs18,19,25 did not report the results in accordance with
what had been described in the Methods section, which was
considered to cause a high risk of bias. Other biases were
considered to be of low risk on account of comparability of
baseline data in 14 RCTs. Overall, the methodological
quality of included RCTs was low (Figs. 2 and 3).
Effects of interventions
Three comparisons were applied in the included RCTs:
acupoint injections compared with Western medicine
(seven RCTs),13,17,22e24,26,29 acupoint injections plus basic
treatment in comparison with basic treatment (eight
RCTs),14e16,18e21,28 and acupoint injection plus basic
treatment with Western medicine plus basic treatment
(three RCTs).12,25,27 Most of the injected medicine and
control therapy varied among RCTs, so data-pooling from
these RCTs for meta-analysis was not meaningful except for
in four RCTs16,18,22,23 (Table 3).
Mortality
One RCT20 compared acupoint injection (aminophylline and
dexamethasone, anisodamine and lidocaine) plus basic
Table 1 Characteristics of included randomized controlled trials.
Study ID Diagnostic criteria Asthma
type
Setting (in/
outpatients)
Participants Design Sample S
( F)
Age (years) Disease
course
(years)
Baseline
data
comparable
Chen LF 201312 Bronchial Asthma Prevention Guide
(2008) by Chinese Medical Association
Respiratory Diseases Branch Asthma
Study Group
NR Outpatients NR Parallel,
two arms
I:73
C:72
Total:145
I /35
C /38
I:57.88  2.80
C:57.50  3.22
I:8.92 
2.78
C:8.67 
2.83
Yes
Dai MS 199513 Diagnostic criteria of Asthma (1992)
by Chinese Medical Association
Respiratory Diseases Branch
Asthma Study Group
Acute
attack
period
NR NR Parallel,
two arms
I:32
C:30
Total:62
3 28 28.4  6.4 12.4  4.6 NR
Guan JH 200914 Children Bronchial Asthma Prevention
Practices (Trial) (1998) by National
Childhood Asthma Prevention Cooperation
NR NR Children Parallel,
two arms
I:48
C:47
Total:95
I /30
C /27
I:3.4  1.9
C:3.5  1.8
NR Yes
Hu YS 201315 Children Bronchial Asthma Prevention
Practices (Trial) (2004) by Chinese
Medical Association Pediatrics Branch
Respiratory Study Group
NR NR Children Parallel,
two arms
I:103
C:103
Total:206
I /45
C /50
I:6.8  2.1
C:6.8  2.1
I:2.2  2.1
C:2.2  2.1
Yes
Hui P 201316 Bronchial Asthma Prevention Guide (2008)
by Chinese Medical Association Respiratory
Diseases Branch Asthma Study Group
Acute
attack
period
Outpatients,
inpatients
NR Parallel,
two arms
I:58
C:58
Total:116
I /28
C /29
I:51.12  10.23
C:49.35  9.75
I:12.12 
5.36
C:10.39 
4.89
Yes
Ji DX 200017 Diagnostic criteria of Asthma by Chinese
Medical Association Respiratory Diseases
Branch Asthma Study Group (CMARDBASG)
NR NR NR Parallel,
three arms
I:24
C1:22
C2:22
Total:68
N I:39.73  10.25
C1:40.56 
11.38
C2:39.85 
10.05
I:8.47 
4.72
C1:8.96 
5.02
C2:8.51 
4.87
Yes
Li YJ 201318 Bronchial Asthma Prevention Guide (2008)
by Chinese Medical Association Respiratory
Diseases Branch Asthma Study Group
NR Outpatients,
inpatients
NR Parallel,
three arms
I1:50
I2:50
C:50
Total:150
I 6/24
I 5/25
C /27
I1:42.2  12.3
I2:44.1  13.1
C:40.2  11.8
I1:12.7 
11.1
I2:13.2 
10.8
C:13.9 
11.5
Yes
Liang AW 200319 Bronchial Asthma Prevention Guide (1997)
by Chinese Medical Association Respiratory
Diseases Branch Asthma Study Group
Acute
attack
period
Inpatients NR Parallel,
two arms
I:35
C:35
Total:70
I /16
C /18
I:36.37(16e60)
C:36.21(15e59)
I:10.11
(2e15)
C:11.03
(2e14)
Yes
Lin DX 200120 NR Acute
attack
period
NR NR Parallel,
two arms
I:58
C:53
Total:111
I /22
C /20
I:32(18e56)
C:32(16e58)
NR NR
26
P.
X
u
e
e
t
a
l.ex
M/
:38
:34
4/
:41
:38
:58
:53
:30
:29
R
1:2
2:2
:23
:19
:17
:36
:33
Qin JL 200421 NR Acute
attack
period
NR NR Parallel,
two arms
I:31
C:31
Total:62
8/34 44(21e75) 0.25e25 Yes
Shen LH 200022 The Definition, diagnosis, severity grade
and therapeutic effect standard(Revised
version) (1993) by Chinese Medical
Association Respiratory Diseases
Branch Asthma Study Group
NR NR NR Parallel,
two arms
I:32
C:30
Total:62
20/12
:19/11
I:42(30e60)
C:43(31e59)
I:11
(0.667e20)
C:10
(0.583e19)
Yes
Shen LH 200123 The Definition, diagnosis, severity grade
and therapeutic effect standard(Revised
version) (1993) by Chinese Medical
Association Respiratory Diseases Branch
Asthma Study Group
NR Outpatients,
inpatients
NR Parallel,
three arms
I1:35
I2:35
C:35
Total:105
:20/15
:19/16
:20/15
I1:19(3e60)
I2:18(2e59)
C:19(2e61)
I1:10(1e20)
I2:11(2e21)
C:12(3e20)
Yes
Sun SZ 201324 Bronchial Asthma Prevention Guide
(1997) by Chinese Medical Association
Respiratory Diseases Branch Asthma
Study Group
NR Outpatients NR Parallel,
two arms
I:40
C:40
Total:80
15/23
:17/25
I:40(17e76)
C:39(18e75)
NR Yes
Tong B 200725 The publisher of the national Guidelines is
Ministry of Health the People’s Republic
of China in1995
Acute
attack
period
Outpatients,
inpatients
NR Parallel,
two arms
I:60
C:30
Total:90
24/36
:13/17
I:45.74(18e65)
C:41.9(18e65)
I:3.8(1e8)
C:3.63
(0.5e8)
Yes
Wang F 199826 The Definition, diagnosis, severity grade
and therapeutic effect standard (Revised
version) (1993) by Chinese Medical
Association Respiratory Diseases Branch
Asthma Study Group
Acute
attack
period
Outpatients,
inpatients and
emergency
patients
NR Parallel,
two arms
I:110
C:98
Total:208
32/78
:28/70
I:37  2.5
C:36  3.5
I:14  6.3
C:14  6.3
NR
Wang HF 200027 Bronchial Asthma Prevention Guide
(1997) by Chinese Medical Association
Respiratory Diseases Branch Asthma
Study Group
Acute
attack
period
Outpatients and
nursing home
patients
Geriatric Parallel,
two arms
I:84
C:86
Total:170
63/21
:60/26
I:60-82
C:60-88
I:16-45
C:15-40
NR
Wang YJ 200528 Children Bronchial Asthma Prevention
Practices (Trial) (2004) by Chinese Medical
Association Pediatrics Branch Respiratory
Study Group
NR Inpatients Children Parallel,
two arms
I:29
C:28
Total:57
R NR NR Yes
Yang ZC 201029 NR Clinical
remission
stage
Outpatients,
inpatients
NR Parallel,
two arms
I:32
C:24
Total:56
24/8
:16/8
I:61(28e82)
C:59(25e80)
I:23(1e40)
C:24(1e41)
Yes
Abbreviations: C, control; F, female; I, intervention; M, male; NR, not reported.
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Table 2 Medications and methods used for acupoint injection in included trials.
Study ID Acupoint injection Control Course of
treatment
Follow-up Effect criteria Outcomes
Chen LF
201312
I: Basic treatment þ BCG-PSN 2 ml,
acupoint 0.5 ml, qod, EX-B1(bilateral),
ST-36(bilateral)
C:Basic treatment þ BCG-PSN
0.7 mg, intramuscular
injection, qod
60 d 6 mon Bronchial
Asthma
Prevention
Guide (2008)
by CMARDBASG
Symptom improvement
rate, ACT score, FEV1%,
PEF, Adverse effect
Dai MS
199513
I: Triamcinolone acetonide 40 mg þ 2%
lidocaine 4 ml, BL13(bilateral)
C: Triamcinolone acetonide
40 mg þ 2% lidocaine 4 ml;
intramuscular injection
3 mon NR NR MTAC, FEV1, FEV1%,
PEF
Guan JH
200914
I: Basic treatment þ BCG-PSN 1 ml, ST-36,
twice a week in first 4 weeks and once a
week in next 4 weeks
C:Basic treatment 12 w 6 mon NR Duration of asthma,
Adverse effect
Hu YS
201315
I: Basic treatment þ Chuankezhi injection
2 mL, BL13(bilateral), ST-36(bilateral),
around the turn, qd
C:Basic treatment 7 d NR Children Bronchial
Asthma Prevention
Practices (Trial)
(2004) by CMAPBRSG
Symptom improvement
rate, PEF, FEV1, FVC
Hui P
201316
I: Basic treatment þ Chuankezhi injection
2 ml, each acupoint 1 ml, EX-B1(bilateral),
CV22, BL13(bilateral), BL23(bilateral),
ST-36(bilateral), a pair of acupoints each time, qod
C:Basic treatment 10 d 3 mon NR FEV1%
Ji DX
200017
I: Vit K3 8 mg, CV22, qod C1:Vit K3 8 mg; intramuscular
injection, qd
C2: Salbutamol, oral
10 d NR Self-defined Symptom improvement
rate, FEV1, FVC;
FEV1/FVC
Li YJ
201318
I1: Basic treatment þ Chuankezhi 2 mL, a pair of
acupoints each time, each acupoint 1 ml(CV22 2 ml),
qod, five times a course and 10 days interval; the
first course: EX-B1, BL13, ST-36, LI11, BL12; the
second course: EX-B1, BL20, ST40, CV22, BL11;
the third course:EX-B1, BL13, ST-36, BL23, LI11
I2: Basic treatment þ person own blood 2 mL,
C:Basic treatment 60 d NR Bronchial Asthma
Prevention Guide
(2008) by CMARDBASG
Symptom improvement
rate, FEV1%
Liang AW
200319
I: Basic treatment þ aminophylline, 0.1 g per
acupoint, EX-B1, BL13(bilateral) (around
the turn), qd
C:Basic treatment 10 d 1 mon Bronchial Asthma
Prevention Guide
(1997) by CMARDBASG
Symptom improvement
rate, FEV1, FVC,VC
Lin DX
200120
I: Basic treatment þ aminophylline 50 mg,
dexamethasone 5 mg, anisodamine 5 mg, lidocaine
40 mg mixture, BL13(bilateral), EX-B1(bilateral), bid
C:Basic treatment 3 d NR Bronchial Asthma
Prevention Guide
by CMARDBASG
Mortality, Symptom
improvement rate,
PEF, FEV1
Qin JL
200421
I: Basic treatment þ anisodamine 0.1 mg, qd, ST-36 C:Basic treatment 7 d NR Bronchial Asthma
Prevention Guide
(1997) by CMARDBASG
Symptom improvement
rate, PEF, FEV1, MTAC
28
P.
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Shen LH
200022
I: BCG-PSN; each acupoint 0.5e1 ml, biw, ST-36, BL13,
EX-B1, around the turn
C: BCG-PSN 1 ml;
intramuscular injection; biw
5 w NR The Definition,
diagnosis, severity
grade and therapeutic
effect standard
(Revised version)
(1993) by CMARDBASG
Symptom improvement
rate
Shen LH
200123
I: BCG-PSN, each acupoint 0.5e1 ml, biw;
ST-36, BL13, EX-B1, around the turn
C1: BCG-PSN 1 ml; intramuscular
injection; biw
C2: Acupuncture, ST-36, BL13,
EX-B1; around
the turn; retaining the needle
for 1e2 min
each time; biw
5 w NR The Definition,
diagnosis, severity
grade and therapeutic
effect standard
(Revised version)
(1993) by CMARDBASG
Symptom improvement
rate
Sun SZ
201324
I:Triamcinolone acetonide 80 mg(2 mL), 2%
lidocaine 2 mL mixed; qw, BL13(bilateral),
EX-B1(bilateral), 1 ml per acupoint
C: Oral antibiotics, aminophylline
and terbutaline spray
4 w NR NR Symptom improvement
rate, PEF, FEV1, FVC,
Adverse effect
Tong B
200725
I: Basic treatment þ Fufang Dansheng injection
1.5e2 ml, qd, EX-B1, BL13, CV22, TE6, ST40,
around the turn
C: Basic treatment þ inhaled
Terbutaline; each time 0.5 ml; tiw
10 d NR Self-defined Symptom improvement
rate, PEF
Wang F
199826
I:Anisodamine 5 mg, dyphylline 125 mg,
dexamethasone 2.5 mg, 2% procaine 2 ml,
qd (severe patients bid), BL13 0.5 ml, BL43 0.5 ml,
EX-B1 1 ml
C: Dexamethasone; 10 mg
intravenous injection, qd or bid
3 d NR NR Symptom improvement
rate, PEF, FEV1, FEV1%
Wang HF
200027
I: Basic treatment þ Triamcinolone acetonide 40 mg,
BL13 (bilateral), EX-B1(bilateral), CV17, each
acupoint 0.5 ml, Nucleotide and Casein 2 ml, ST-36
(bilateral), 1 ml per acupoint,
once a month
C: Basic treatment þ Inhaled
Beclomethasone and salbutamol
3 m 1 y Bronchial Asthma
Prevention Guide
(1997) by CMARDBASG
Symptom improvement
rate, Adverse effect
Wang YJ
200528
I: Basic treatment þ Recombinant Human
Interferon eg, qod, EX-B1(bilateral), BL13,
fifty thousand units per acupoint each time
C:Basic treatment 10 d NR Children Bronchial
Asthma Prevention
Practices (Trial)
(2004) by CMAPBRSG
Symptom improvement
rate, MTAC
Yang ZC
201029
I: Huangqi injection (ST-36 5e10 ml, ST40 5e10 ml),
Yuxingcao injection(ST-36 5e10 ml, ST40 5e10 ml),
Mycobacterium Phlei F.U.36 Injection(Utilin“s”)
(1 ml:172 g) (CV22 0.5 ml, BL13 0.5 ml, EX-B1
(bilateral)0.5 ml), Group A: ST-36, CV22, BL13;
Group B:ST-36, EX-B1, ST40, two group alternate, qod.
C: Ketotifen, 1 mg, bid, oral;
Theophylline Sustained Release
0.1 g, bid, oral; Beclomethasone
200ug and Ventolin 200ug, tid,
alternate inhaled
2e3
mon
1 y Self-defined Symptom improvement
rate, FEV1,FVC,VC,
Adverse effect
Abbreviations: ACT, asthma control test; bid, twice a day; biw, twice a week; BCG-PSN, BCG Polysaccharide and Nucleic Acid injection; C, control; CMARDBASG, Chinese Medical As-
sociation Respiratory Diseases Branch Asthma Study Group; CMAPBRSG, Chinese Medical Association Pediatrics Branch Respiratory Study Group; d, days; FVC, forced vital capacity; FEV1,
forced expiratory volume in one second; I, intervention; MTAC, the mean time that asthma; NR, not reported; mon, month; PEF, peak expiratory flow; qd, once a day; qod, once two days;
qw, once a week; tiw, three times a week; VC, vital capacity; w, weeks; y, year.
Note: Basic treatment involved symptomatic treatments such as reducing inflammation, resolving phlegm, relieving wheezing and panting.
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Fig. 2 Risk of bias. Authors’ judgment about each risk of bias item for each included RCT.
30 P. Xue et al.treatment with basic treatment. It showed that four pa-
tients died in the control group whereas no one died in the
treatment group, but a significant difference was not
observed.
Symptom improvement rate
A meta-analysis was conducted by pooling data from two
RCTs22,23 that tested the symptom improvement rate of
acupoint injection of BCG-PSN for asthma compared with
intramuscular injection of BCG-PSN (RR, 1.55; 95% CI,
1.22e2.22; I2 Z 0%).
Four RCTs18,19,21,28 compared acupoint injection plus
basic treatment with basic treatment, yet only one RCT19
showed that acupoint injection of aminophylline
enhanced the symptom improvement rate significantly (RR,
1.21; 95% CI, 1.02e1.45).
One RCT27 comparing acupoint injection (triamcinolone
acetonide plus nucleotide and casein) plus basic treatment
with inhaled (beclomethasone and salbutamol) plus basic
treatment and another RCT12 comparing acupoint injection
(BCG-PSN) plus basic treatment with intramuscular injec-
tion (BCG-PSN) plus basic treatment did not show signifi-
cant differences in the symptom improvement rate
between groups.
ACT
One RCT12 in which acupoint injection of BCG-PSN plus
basic treatment was compared with intramuscular injection
of BCG-PSN plus basic treatment showed a significant dif-
ference in improvement of ACT score (MD, 1.02; 95% CI,
0.22e1.82).
Duration of asthma
One RCT14 comparing acupoint injection of BCG-PSN in
combination with basic treatment with basic treatment
showed a significant difference in improving the attack
time of asthma (MD, 1.45 days; 95% CI, 2.01 to 0.89).
Mean time that asthma was controlled
One RCT13 comparing acupoint injection of triamcinolone
acetonide plus lidocaine with the same medicines injected
via the intramuscular route showed significant differences
for improving the MTAC (MD, 1.50 days; 95% CI, 1.90 to
1.10).
Two RCTs21,28 comparing acupoint injection (anisod-
amine and recombinant human interferon-g, respectively)
plus basic treatment with basic treatment showedsignificant differences for improving the MTAC (MD, 1.50
days and 95% CI, 2.36 to 0.64; MD, 2.48 and 95% CI,
4.03 to 0.93, respectively).
PEF
Three RCTs13,24,26 compared acupoint injection with West-
ern medicine, two of which13,26 showed acupoint injection
had a superior effect, whereas the other RCT24 found no
significant difference between groups. Acupoint injection
(anisodamine and dyphylline and dexamethasone and pro-
caine) compared with intravenous injection (dexametha-
sone) and acupoint injection (triamcinolone acetonide and
lidocaine) compared with intramuscular injection (triam-
cinolone acetonide and lidocaine) had significant differ-
ences with regard to improvement in PEF (MD, 0.79 L/s and
95% CI, 0.59e0.99; MD, 1.12 L/s and 95% CI, 1.02e1.22,
respectively).
Three RCTs15,20,21 compared acupoint injection plus
basic treatment with basic treatment, of which one15
showed that acupoint injection (Chuankezhi) had a signifi-
cant difference (MD, 0.41 L/s; 95% CI, 0.27e0.55), whereas
the other two20,21 found no significant differences between
groups.
Two RCTs12,25 compared acupoint injection plus basic
treatment with Western medicine plus basic treatment:
both RCTs found no significant differences between
treatments.
FEV1
Five RCTs13,17,24,26,29(six comparisons) compared acupoint
injection with Western medicine, three of which13,26,29
showed that acupoint injection had significant differences
whereas the other two found no significant differences.
Acupoint injection (anisodamine and dyphylline and dexa-
methasone and procaine) compared with intravenous in-
jection (dexamethasone), acupoint injection
(triamcinolone acetonide and lidocaine) compared with
intramuscular injection (triamcinolone acetonide and lido-
caine) and acupoint injection (Utilin’s and Huangqi injec-
tion and Yuxingcao injection) compared with oral (ketotifen
plus theophylline sustained-release tablets) and inhaled
(beclomethasone plus ventolin) treatment had significant
differences for improving FEV1 (MD, 0.50 L and 95% CI,
0.40e0.61; MD, 0.62 L and 95% CI, 0.54e0.70; MD, 0.28 L
and 95% CI, 0.09e0.47, respectively).
Four RCTs15,19e21 compared acupoint injection in com-
bination with basic treatment with basic treatment,
Fig. 3 Breakdown of each type of risk of bias identified in the
included studies. Note: “þ”: low risk of bias; “?”: unclear risk
of bias; “” high risk of bias.
Acupoint injection for asthma 31three15,19,21 of which showed that acupoint injection had
significant differences while the other RCT found no sig-
nificant differences. Acupoint injection with Chuankezhi,
aminophylline or anisodamine showed significant differ-
ences for improving FEV1 (MD, 0.36 L and 95% CI 0.12e0.60;
MD, 0.58 L and 95% CI, 0.31e0.85; MD, 0.40 L and 95% CI
0.06e0.74, respectively).
FVC
Three RCTs17,24,29 (four comparisons) compared acupoint
injection with Western medicine, one of which29 showed
that acupoint injection (utilins and Huangqi injection and
Yuxingcao injection) compared with oral medications
(ketotifen plus theophylline sustained-release tablets) and
inhaled medications (beclomethasone plus ventolin) had
significant differences in terms of improving FVC (MD,
0.34 L; 95% CI, 0.09e0.59), whereas the other RCTs found
no significant differences.
Two RCTs15,19 compared acupoint injection in combina-
tion with basic treatment with basic treatment, and both
showed that acupoint injection (Chuankezhi and aminoph-
ylline) had significant differences in terms of improving FVC
(MD, 0.54 L and 95% CI, 0.31e0.77; MD, 0.81 L and 95% CI,
0.60e1.02, respectively).
FEV1/FVC
One RCT17 (two comparisons) compared acupoint injection
with Western medicine: acupoint injection did not improve
FEV1/FVC significantly.
FEV1%
Two RCTs13,26 compared acupoint injection with Western
medicine. They showed that acupoint injection (anisod-
amine and dyphylline and dexamethasone and procaine)
compared with intravenous injection (dexamethasone) and
acupoint injection (triamcinolone acetonide and lidocaine)
compared with intramuscular injection (triamcinolone
acetonide and lidocaine) had significant differences in
terms of improving FEV1% (MD, 10.50 and 95% CI
6.05e14.95; MD, 11.10 and 95% CI, 9.88e12.32,
respectively).
A meta-analysis was conducted by pooling data from two
RCTs16,18comparing acupoint injection of Chuankezhi in
combination with basic treatment with basic treatment.
Significant differences in terms of improvement in FEV1%
(MD, 4.76; 95% CI, 2.84e6.68, random-effects model,
I2 Z 77%) were noted.
One RCT12 compared acupoint injection of BCG-PSN plus
basic treatment with intramuscular injection of BCG-PSN
plus basic treatment, but did not show acupoint injection
improved FEV1% significantly.
VC
One RCT29 compared acupoint injection (utilins and
Huangqi injection and Yuxingcao injection) with oral med-
ications (ketotifen plus theophylline sustained-release
tablets) and inhaled medications (beclomethasone plus
ventolin), and showed significant differences in terms of
improving VC (MD, 0.72 L; 95% CI, 0.52e0.92).
One RCT19 compared acupoint injection in combination
with basic treatment with basic treatment, and showed
Table 3 Effect estimates of acupoint injection for asthma.
Outcomes and comparisons No. of
studies
No. of
participants
Effect
estimates
P Study ID
1. Mortality
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection aminophylline plus dexamethasone plus
anisodamine plus lidocaine injection þ Basic treatment
vs Basic treatment
1 111 MD:0.03 [0.35, 0.41] 0.88 Lin DX 200120
2. Symptom improvement rate
Acupoint injection vs Western medicine
Acupoint injection BCG-PSN vs intramuscular injection BCG-PSN 2 132 RR: 1.55 [1.22, 2.22] 0.001 Shen LH 200022;
Shen LH 200123
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection anisodamine þ Basic treatment vs Basic treatment 1 62 RR: 1.15 [0.98, 1.36] 0.09 Qin JL 200421
Acupoint injection Recombinant Human Interferon g þ Basic treatment
vs Basic treatment
1 57 RR: 1.13 [0.93, 1.38] 0.22 Wang YJ 200528
Acupoint injection Chuankezhi þ Basic treatment vs Basic treatment 1 100 RR: 1.15 [0.98, 1.35] 0.09 Li YJ 201318
Acupoint injection aminophylline þ Basic treatment vs Basic treatment 1 70 RR: 1.21 [1.02, 1.45] 0.03 Liang AW 200319
Acupoint injection þ Basic treatment vs Western medicine þ Basic treatment
Acupoint injection triamcinolone acetonide plus nucleotide and casein þ Basic
treatment VS inhaled beclomethasone plus salbutamol þ Basic treatment
1 170 RR: 1.02 [0.93, 1.13] 0.63 Wang HF 200027
Acupoint injection BCG-PSN þ Basic treatment vs intramuscular injection
BCG-PSN þ Basic treatment
1 145 RR: 1.09 [1.00, 1.20] 0.05 Chen LF 201312
3. ACT
Acupoint injection þ Basic treatment vs Western medicine þ Basic treatment
Acupoint injection BCG-PSN þ Basic treatment vs intramuscular injection
BCG-PSN þ Basic treatment
1 145 MD: 1.02 [0.22, 1.82] 0.01 Chen LF 201312
4. Duration of asthma (d)
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection BCG-PSN þ Basic treatment vs Basic treatment 1 95 MD: 1.45[2.01, 0.89] 0.001 Guan JH 200914
5. MTAC (d)
Acupoint injection vs Western medicine
Acupoint injection triamcinolone acetonide plus lidocaine vs intramuscular
injection triamcinolone acetonide plus lidocaine
1 62 MD: 1.50 [1.90, 1.10] 0.001 Dai MS 199513
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection anisodamine þ Basic treatment vs Basic treatment 1 62 MD: 1.50 [2.36, 0.64] 0.001 Qin JL 200421
Acupoint injection Recombinant Human Interferon g þ Basic treatment
vs Basic treatment
1 57 MD: 2.48 [4.03, 0.93] 0.002 Wang YJ 200528
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6. PEF (L/s)
Acupoint injection vs Western medicine
Acupoint injection triamcinolone acetonide vs oral antibiotics, aminophylline
plus terbutaline spray
1 80 MD:0.19[0.46,0.84] 0.56 Sun SZ 201324
Acupoint injection anisodamine plus dyphylline plus dexamethasone plus
procaine vs intravenous injection dexamethasone
1 208 MD:0.79[0.59,0.99] 0.001 Wang F 199826
Acupoint injection triamcinolone acetonide plus lidocaine vs intramuscular
injection triamcinolone acetonide plus lidocaine
1 62 MD:1.12[1.02,1.22] 0.001 Dai MS 199513
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection Chuankezhi þ Basic treatment vs Basic treatment 1 206 MD:0.41[0.27, 0.55] 0.001 Hu YS 201315
Acupoint injection aminophylline plus dexamethasone plus anisodamine plus
lidocaine injection þ Basic treatment vs Basic treatment
1 111 MD:0.03 [0.35, 0.41] 0.88 Lin DX 200120
Acupoint injection anisodamine þ Basic treatment vs Basic treatment 1 62 MD:0.70 [0.38, 1.78] 0.20 Qin JL 200421
Acupoint injection þ Basic treatment vs Western medicine þ Basic treatment
Acupoint injection BCG-PSN þ Basic treatment vs intramuscular injection
BCG-PSN þ Basic treatment
1 145 MD:0.05 [0.03, 0.13] 0.23 Chen LF 201312
Acupoint injection Fufang Dansheng þ Basic treatment vs inhaled Terbutaline þ
Basic treatment
1 90 MD:0.23 [0.29, 0.75] 0.38 Tong B 200725
7. FEV1(L)
Acupoint injection vs Western medicine
Acupoint injection triamcinolone acetonide vs Oral antibiotics, aminophylline
plus terbutaline spray
1 80 MD:0.10[0.14,0.34] 0.42 Sun SZ 201324
Acupoint injection Vit B3 vs intramuscular injection Vit B3 1 46 MD:0.31[0.19,0.81] 0.23 Ji DX 200017
Acupoint injection Vit B3 vs oral salbutamol 1 46 MD:0.36[0.13,0.85] 0.15 Ji DX 200017
Acupoint injection anisodamine plus dyphylline plus dexamethasone plus
procaine vs intravenous injection dexamethasone
1 208 MD:0.50[0.40,0.61] 0.001 Wang F 199826
Acupoint injection triamcinolone acetonide plus lidocaine vs intramuscular
injection triamcinolone acetonide plus lidocaine
1 62 MD:0.62[0.54,0.70] 0.001 Dai MS 199513
Acupoint injection utilins plus Huangqi injection plus Yuxingcao injection vs
oral ketotifen plus theophylline sustained release tablets plus inhaled
beclomethasone plus ventolin
1 56 MD:0.28[0.09,0.47] 0.004 Yang ZC 201029
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection Chuankezhi þ Basic treatment vs Basic treatment 1 206 MD:0.36[0.12, 0.60] 0.003 Hu YS 201315
Acupoint injection aminophylline þ Basic treatment vs Basic treatment 1 70 MD:0.58 [0.31, 0.85] 0.001 Liang AW 200319
Acupoint injection aminophylline plus dexamethasone plus anisodamine plus
lidocaine Injection þ Basic treatment vs Basic treatment
1 111 MD: 0.14 [0.37, 0.09] 0.24 Lin DX 200120
Acupoint injection anisodamine þ Basic treatment vs Basic treatment 1 62 MD:0.40 [0.06, 0.74] 0.02 Qin JL 200421
8. FVC(L)
Acupoint injection vs Western medicine
Acupoint injection triamcinolone acetonide vs Oral antibiotics, aminophylline
plus terbutaline spray
1 80 MD:0.03[0.24,0.30] 0.83 Sun SZ 201324
(continued on next page)
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Table 3 (continued )
Outcomes and comparisons No. of
studies
No. of
participants
Effect
estimates
P Study ID
Acupoint injection Vit B3 vs intramuscular injection Vit B3 1 46 MD:0.14[0.39,0.67] 0.60 Ji DX 200017
Acupoint injection Vit B3 vs oral salbutamol 1 46 MD:0.16[0.38,0.70] 0.56 Ji DX 200017
Acupoint injection utilins plus Huangqi injection plus Yuxingcao injection vs
Oral ketotifen plus Theophylline Sustained Release tablets plus inhaled
Beclomethasone plus Ventolin
1 56 MD:0.34[0.09,0.59] 0.007 Yang ZC 201029
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection Chuankezhi þ Basic treatment vs Basic treatment 1 206 MD:0.54[0.31, 0.77] 0.001 Hu YS 201315
Acupoint injection aminophylline þ Basic treatment vs Basic treatment 1 70 MD:0.81 [0.60, 1.02] 0.001 Liang AW 200319
9. FEV1/FVC
Acupoint injection vs Western medicine
Acupoint injection Vit B3 vs intramuscular injection Vit B3 1 46 MD:6.04[1.30,13.38] 0.11 Ji DX 200017
Acupoint injection Vit B3 vs oral salbutamol 1 46 MD:6.65[0.75,14.05] 0.08 Ji DX 200017
10. FEV1%
Acupoint injection vs Western medicine
Acupoint injection anisodamine plus dyphylline plus dexamethasone plus procaine vs
intravenous injection dexamethasone
1 208 MD:10.50[6.05,14.95] 0.001 Wang F 199826
Acupoint injection triamcinolone acetonide plus lidocaine vs intramuscular injection
triamcinolone acetonide plus lidocaine
1 62 MD:11.10[9.88,12.32] 0.001 Dai MS 199513
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection Chuankezhi þ Basic treatment vs Basic treatment 2 216 MD:4.76 [2.84, 6.68] 0.04 Hui P 201316;
Li YJ 201318
Acupoint injection þ Basic treatment vs Western medicine þ Basic treatment
Acupoint injection BCG-PSN þ Basic treatment vs intramuscular injection
BCG-PSN þ Basic treatment
1 145 MD:0.17 [0.64, 0.98] 0.68 Chen LF 201312
11. VC(L)
Acupoint injection vs Western medicine
Acupoint injection utilins plus Huangqi injection plus Yuxingcao injection vs oral
ketotifen plus theophylline sustained release tablets plus inhaled
beclomethasone plus ventolin
1 56 MD:0.72[0.52,0.92] 0.001 Yang ZC 201029
Acupoint injection þ Basic treatment vs Basic treatment
Acupoint injection aminophylline þ Basic treatment vs Basic treatment 1 70 MD:0.80 [0.58, 1.02] 0.001 Liang AW 200319
Abbreviations: ACT, asthma control test; BCG-PSN, BCG Polysaccharide and Nucleic Acid injection; d, days; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MD,
mean difference; PEF, peak expiratory flow; RR, relative risk; VC, vital capacity.
Note: Basic treatment involved symptomatic treatments such as reducing inflammation, resolving phlegm, relieving wheezing and panting.
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Acupoint injection for asthma 35that acupoint injection (aminophylline) improved VC
significantly (MD, 0.80 L; 95% CI, 0.58e1.02).
Safety
Five RCTs12,14,24,27,29 reported adverse events, and showed
no significant differences between the acupoint injection
group and control group. Adverse events in the acupoint
injection group included local skin redness, swelling, and
pain, all of which could be relieved rapidly. Serious adverse
events were not reported in the included RCTs.
Discussion
This systematic review identified the effectiveness of acu-
point injection alone or in combination with basic treat-
ment for asthma patients.
Eleven outcomes were applied to compare the effec-
tiveness of acupoint injection involving three types of com-
parisons. Results from the included eighteen RCTs were
inconsistent. This may have been related to the different
medicines and acupoint injections employed in different
RCTs. In terms of the symptom improvement rate, only two
RCTs showed acupoint injection to be superior to Western
medicine in patients with asthma. The diversity of patients
and variety of outcome measures may also explain those
results. With regard to ACT results, duration of asthma, and
the MTAC, acupoint injection used alone or in combination
with basic treatment was superior to Western medicine
alone or in combination with basic treatment. However, we
failed to find RCTs assessing QoL in patients with asthma. In
terms of LFTs, the results from the included eighteen RCTs
were inconsistent. Acupoint injection may have certain ef-
fects on improving ACTresults, attack time of asthma,MTAC,
and LFTs of patients with asthma. However, considering the
relatively poor quality of included RCTs, acupoint injection
should be used selectively for asthma treatment. Thirteen
out of the eighteen RCTs did not report the outcome of
adverse events. Hence, the safety of acupoint injection for
asthma remains unclear (though some RCTs showed no sig-
nificant differences between the acupoint injection group
and control group in terms of adverse reactions).
The methodological quality of included RCTs was not
high. Most RCTs did not provide sufficient information about
generation of randomized sequences or allocation
concealment. Hence, selection bias could have been pre-
sent in RCTs. Performance bias was a high risk because no
study used a placebo or other methods to blind participants
and personnel to the study protocol. Selection of a control
to blind participants and personnel from acupoint injection
is difficult, but it is important to blind the outcome asses-
sors and statistician. Also, information regarding detection
bias was unclear. Such non-optimal reporting can lead to
other biases in assessment. Thus, we highly recommend
further RCTs report according to CONSORT and STRICTA
statements.30,31
Our systematic review had limitations. First, though
considerable efforts were made to include all RCTs
involving acupoint injection for asthma treatment, we
cannot be sure data collection was comprehensive. In
addition, owing to the diversity of acupoints and injections,we cannot recommend acupoint injection at specific acu-
points or with specific injections that are effective for
asthma treatment. Moreover, we cannot provide evidence
of acupoint injection for patients with asthma in terms of
QoL and long-term effectiveness because of the absence of
information on QoL and follow-up data. Finally, our sys-
tematic review was limited with regard to generalization of
acupoint injection for asthma treatment owing to low
methodological quality and poor reporting.
Future RCTs focusing on acupoint injection for asthma
treatment should pay more attention to QoL and safety. A
follow-up period is necessary to evaluate the long-term
effect of acupoint injection for asthma treatment. Also,
RCTs with rigorous study designs and high methodological
quality should be conducted to avoid potential exaggera-
tion of the therapeutic effects of acupoint injection for
asthma treatment.32 Reporting of RCTs using acupoint in-
jection should be in accordance with CONSORT and STRICTA
standards.30,31 Further research might compare different
acupoints for optimal treatment of asthma.
Conclusions
Based on existing evidence, acupoint injection may be
effective for improving ACT results, duration of asthma,
MTAC, and LFTs, but the safety of acupoint injection is not
clear. The RCTs included in this systematic review had small
sample sizes, as well as poor methodological quality and
reporting. Thus, rigorously designed, large RCTs are needed
to verify the efficacy of acupoint injection for asthma
treatment, and to monitor adverse reactions in a stan-
dardized manner. In addition, CONSORT and STRICTA
guidelines30,31 should be followed for objective reporting of
results.
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